4 May 2021 - Gilead’s antibody-drug conjugate Trodelvy (sacituzumab govitecan) has won the Ministry of Food and Drug Safety’s designation as an orphan drug, which could accelerate the local release of the drug.

The ministry said on Monday that it newly designated three drugs, including Trodelvy, as orphan drugs. 

Trodelvy is indicated for the treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer.

Read Korea Biomedical Review article